It is now well established that the majority of IBD patients are responsive to the anti-TNFα therapy, but a significant percentage (up to 40% in some groups of UC) can be defined as primary non-responsive.21, 22 In this study we have described a potentially important mechanism linking TNFα-mediated inflammatory cytokine control through IL-1β. This evidence concerns the gene IL1B and inflammatory bowel disease.